Signant Health Neurology and Alzheimer’s Disease Scientific Advisory Board

Mike Nolte joined in 2018 as the Chief Executive Officer. Mike is a seasoned operational leader whose career spans the healthcare, technology and financial services industries. Mike recently serving as Chief Executive Officer at Influence Health. Prior to that position, Mike served as President, Chief Operating Officer and Director of the public company MedAssets (MDAS), prior to which he spent 7 years at General Electric (GE), including roles as Vice President and General Manager of Americas Services for GE’s Healthcare IT business, where he led more than 1,700 teammates focused on GE’s $900 million healthcare software portfolio, VP and GM of GE’s $230 million enterprise revenue cycle software business and VP and GM of marketing and product management for GE Healthcare IT’s ambulatory segment. He also spent five years with McKinsey & Company and started his career as a U.S. Army Officer, finishing up as a Captain and Company Commander for an airborne, rapid deployment, medical supply chain and maintenance organization. Mike holds a Master of Business Administration from The University of Chicago Booth School of Business and a Bachelor’s Degree from the University of Notre Dame.

Dr. Jeffrey Cummings

Chairman Neurology and AD SAB

Mitch Blumenfeld oversees Finance, Quality and all Legal and Regulatory Affairs. He joined from PCI Pharma Services, the world’s largest provider of outsourced pharmaceutical packaging and related services where he was responsible for all financial management for 18 facilities across North America, Europe and Australia. He led PCI’s finance functions during a period of rapid growth, including a ten-fold increase in EBITDA and the successful completion of five acquisitions in the US, UK, Ireland and Australia. Prior to his time with PCI, Mitch worked for AmerisourceBergen as the Senior Vice President and CFO of the Drug Corporation and led the integration and finance functions for World Courier, the world leader in global cold chain and clinical trial logistics with offices in over 140 countries. Mitch started work with GE, having a career spanning 15 years and roles in the US and Europe with the Appliances, Lighting, Information Services and Water Technology businesses as well as five years in the Corporate Audit Staff. He is a graduate of GE’s Edison Engineering Program and Advanced Courses in Engineering. Mitch holds a Bachelor of Science in Computer Science Engineering from Bucknell University and a Master of Science in Computer Science & Applications from Virginia Tech.

John Harrison, CSci CPsychol AFBPsS

Christopher L. Crucitti, MS, leads the commercial functions of the organization, as well as the go-to-market strategy, to drive the continued growth of our already market-leading clinical technology solutions platform. Chris brings significant experience and expertise in the clinical and R&D domains. He has led organizations to significant revenue and profitability growth, while maintaining a high level of customer service and quality delivery. He joined from Science Exchange, having served as Chief Commercial Officer for the world’s largest enterprise platform to manage outsourced R&D services. Prior to Science Exchange, he held various senior executive-level positions and oversight of commercial functions within the CRO industry (most notably Worldwide Clinical Trials and inVentiv Health Clinical) overseeing solutions spanning technology, consulting, strategic resourcing, clinical development and R&D. Chris holds a Master of Science from American University and a Bachelor of Science from Ithaca College.

Marwan Sabbagh, MD

Jeffrey L. Cummings, MD, ScD, is Founding Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio.  He is Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Cummings is Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience. Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials.

Dr. John Harrison is an Honorary Senior Lecturer in the Dept. of Medicine at Imperial College London and Principal Consultant at Metis Cognition Ltd.  Metis is an applied psychology practice established to advise pharmaceutical companies on the selection and successful integration of cognitive testing into their development programs.  At the time of writing Metis provide consultancy to more than 30 companies involved in the development of new drugs for indications including Alzheimer’s disease, depression, schizophrenia and Parkinson’s disease

Marwan Noel Sabbagh, MD, board certified neurologist and geriatric neurologist, hopes to work himself out of a job. Considered one of the leading experts in Alzheimer’s and dementia, he is the Camille and Larry Ruvo Endowed Chair for Brain Health and Director of Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas.

Susie Robinson oversees human resources for over 1500 employees worldwide where she is focused on executing contemporary people strategies that will accelerate innovation, scale a powerful business and remain focused on expert service for customers. With more than 15 years as a Chief Human Resources Officer and 20+ years as an HR practitioner and advisor, she is a decisive, energetic, results-driven business leader with an eye for talent and a skill for transforming organizations. She has led HR, communications, operational and technical teams of 5 to 120 members in multi-divisional, multi-cultural operations with workforces from 700-6K+ in The Americas, Europe, and Asia. Ms. Robinson holds a Bachelor of Arts in Psychology from the California State University at Fullerton. She serves as an Advisory Board member of the Wharton Center for Human Resources Research Advisory Group of the University of Pennsylvania and as Vice Chairman of the Board of the Women’s Business Development Council.

Mary Sano, PhD

Lawrence Miller is the Chief Technology Officer for Signant Health. His career has been focused on leading and scaling commercial, global technology organizations. Lawrence started as a quantitative analytics developer at JP Morgan Chase, eventually leading the development for one of the firm’s electronic trading platforms. In 2004 he joined BlackRock, where he was a Managing Director, overseeing the Development Services team for Aladdin, BlackRock’s asset management platform and the core of its successful SaaS business. While at BlackRock, Lawrence was involved in the formation of Symphony Communication Services and served as a Board Observer prior to joining the startup. At Symphony, Lawrence was Chief Security Officer, overseeing the firm’s security program, managing platform operations, and leading the firm’s regulatory and government affairs. Lawrence also served on the Commodity Futures Trading Commission’s TAC Cybersecurity Subcommittee, the Board of the FINOS FinTech Open Source Foundation, and currently serves on the University of Chicago’s Institute for Molecular Engineering Council. Lawrence holds an MS in Computer Science from The George Washington University, and a BA in Physics from the University of Chicago.

Professor Craig Ritchie

Daniel Weintraub, MD

James Jay oversees the global service business. He has 18 years of experience building successful software solutions for healthcare and life sciences. For the preceding six years he led the Global Imaging IT business at Agfa HealthCare, where he transformed the business strategy while creating a new market segment and established early market leadership. Prior to Agfa, James spent 13 years at GE, where he led the Global Cardiology IT business and held other roles across R&D and program management. James has an Master of Business Administration in Global Management from American Intercontinental University and a Bachelor of Science in Computer Science from the University of Oregon.

Dr. Mary Sano is Professor of Psychiatry and the Director of the Alzheimer’s Disease Research at Mount Sinai School of Medicine. She is also the Director of Research and Development at the Bronx Veterans Administration Hospital. Currently she is the director of a national multi-center study known as CLASP (Cholesterol Lowering in Alzheimer’s Disease to Slow Progression). Dr. Sano is a neuropsychologist by training and has been involved in designing and conducting clinical trials for Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment of aging.

Chair of the Psychiatry of Ageing and Director of the Centre for Dementia Prevention, currently Professor of the Psychiatry of Ageing at the University of Edinburgh having moved from his role as Senior Lecturer in the Centre for Mental Health at Imperial College London in October 2014. Professor Ritchie is a leading authority on Clinical Trials in Dementia and has been senior investigator on over 30 drug trials of both disease modifying and symptomatic agents for that condition. This emerged from his ongoing clinical leadership of the MPAC (Metal Protein Attenuating Compound) pipeline for Prana Biotechnology dating back to 1998 when he worked as a Senior Visiting Research Fellow at the Mental Health Research Institute in Victoria, Australia. He has sat on advisory boards of numerous pharmaceutical companies, biotechs and clinical research organizations with an in interest in developing drugs and trials infrastructure for Alzheimer’s disease.

Dr. Daniel Weintraub is Assistant Professor of Psychiatry at the University of Pennsylvania and Fellow at the University of Pennsylvania Institute of Aging. He completed medical, psychiatry residency, and geriatric psychiatry fellowship training at the University of Maryland. His areas of research interest include the psychiatric and cognitive complications of Parkinson’s disease. He is current recipient of a 5-year Career Development Award (K23) from the National Institute of Mental Health (NIMH) titled “Depression Diagnosis and Treatment in Parkinson Disease.” In addition, he is currently Coordinating Investigator for a multi-site international industry-sponsored study of the frequency and correlates of impulse control disorders in PD. Dr. Weintraub has also served on three Movement Disorder Society (MDS) task forces to revise and make recommendations for the assessment of non-motor symptoms in Parkinson’s disease, and is a member of the Scientific Review Committee of the Parkinson Study Group.

Jim Primerano oversees the delivery of the eClinical solutions portfolio. Jim has 20 years of clinical research and technology experience, leading teams to bring innovative solutions to the pharmaceutical industry in support of clinical development. Prior to joining, Jim was Sr. Director of Product Strategy with Medidata Solutions, where he was responsible for driving product portfolio expansion. Jim holds a Bachelor of Arts in Biology from the University of Pennsylvania and a Master of Business Administration in Global Business from Rider University.

Rhoda Au, Ph.D.

Rauha Tulkki-Wilke leads cross-functional design and development of eCOA solutions for client and therapeutic area needs, combining science and patient experience with leading technology. Rauha has close to 20 years of experience with all that eCOA encompasses and has a genuine interest in digital health. Prior to moving to the pharmaceutical industry, she developed solutions for anesthesia management and neonatal intensive care. Rauha holds a Master of Science in Biophysics and Biomedical Engineering.

Clinical Professor of Psychiatry, George Washington University.

Dr. David Daniel provides overall scientific, clinical and strategic direction for our solutions. Dr. Daniel was the founder and President of Global Learning, LLC which was acquired by United BioSource Corporation in July 2006. He formerly served as Medical Director of the NIMH Neuroscience Center at Saint Elizabeth’s, Director of Clinical Trials for the Stanley Foundation and was a founding Principal of Best Practice, LLC. For over 30 years, Dr. Daniel has supervised and trained raters in psychiatric clinical trials globally. He has published numerous scientific articles involving clinical trials and investigations of the psychopathology of mental illness. He has received patent protection for new treatment approaches in epilepsy, anxiety disorders and psychotic disorders. Dr. Daniel graduated Phi Beta Kappa and Magna Cum Laude from Emory University and obtained his medical school and psychiatry post-graduate training at Vanderbilt University, where he served as chief resident. He was a medical staff fellow and senior staff fellow within the intramural program of the National Institute of Mental Health (DIRP, NIMH) for five years.

Professor, Epidemiology, Boston University School of Public Health. Center Faculty Member, Framingham Heart Study.

Dr. Au’s research interests are focused on aging and dementia, and include relating cardiovascular risk factors, brain MRI measures, and neuropathology to cognitive performance. She is also interested in merging research and technology as the path toward innovative science.